H istorically, surgical repair and rescue with extracorporeal membrane oxygenation (ECMO) support has been withheld from some patients with congenital heart disease (CHD) and genetic conditions (GCs) (1) . Over time, GCs that excluded patients from cardiac surgical palliation have changed (1) . Recognizable syndromes, extracardiac malformations, and chromosomal anomalies associated with GCs occur in approximately 20-30% of children with CHD (2, 3) . Advances in cytogenetic testing and other methods are increasing recognition of GCs (4, 5) . Although studies may vary by specific genetic diagnosis, patient age, and anatomic lesion, most report greater morbidity and mortality risk among children with GCs (5).
Perioperative ECMO use among children with CHD is 2.7-3% of surgical cases (6, 7) . Assessment of perioperative risk of mortality or need for ECMO among children with GC and CHD is complex, because the number of GCs that have associated congenital heart malformation is large but the number of surgical patients with the same GCs and cardiac diagnosis are small, with the exception of trisomy 21 (T21). In the past, providers were reluctant to offer ECMO to patients with GCs (8) . However, recent surveys report changing attitudes, including the use of ECMO in children with trisomy 13 or 18 (T13/18) (1).
Using the Pediatric Health Information System (PHIS) database, we identified over 150,000 heart surgeries and 4,300 ECMO runs in the perioperative period. The PHIS database provides a unique opportunity to describe trends in surgical care and ECMO use over the last 10-year time period for patients with known GCs.
Our study goals are to describe trends regarding receipt of cardiac surgery by children with known GCs and to characterize ECMO use and outcomes for patients with and without GCs who had cardiac surgery. We hypothesized an increasing trend in surgical procedures for children with CHD and GCs over the past decade and that patients with GCs would be less likely to be offered perioperative ECMO support and more likely to die without the use of ECMO.
MATERIALS AND METHODS

Study Design and Setting
We conducted a retrospective cross-sectional analysis using PHIS database to identify cardiac surgical admissions discharged between January 1, 2004, and June 30, 2014. The Children's Hospital Association developed and maintains PHIS database, which currently contain data from 49 tertiary-care children's hospitals located all over the United States. Participating hospitals provide both administrative data, such as patient and hospital demographics, International Classification of Disease, 9th Edition (ICD-9) codes, length of stay, and discharge disposition. Additional admission characteristics are available such as complex chronic conditions according to Feudtner et al (9) and Risk Adjustment for Congenital Heart Surgery (RACHS) scores as described by Jenkins (10) . Data submitted to PHIS database are subject to several reliability and accuracy checks ensuring data integrity. This study obtained data without any patient identifying information compliant with a deidentified dataset that the University of Utah Institutional Review Board excludes from need for human study oversight.
Patient Selection Criteria
Using ICD-9 procedure codes, we identified cardiac surgical admissions for children 18 years old or younger discharged from January 1, 2004, to December 31, 2014, defined as being assigned a RACHS score 1-6 or having an ICD-9 code for myocarditis or cardiomyopathy (n = 150,717). Surgical complexity was stratified using the RACHS score as assigned by PHIS database (10) . ECMO was determined by ICD-9 procedure code 39.35.
Only subjects with a RACHS score greater than 1 and the surgical procedures listed in Appendix 1A (Supplemental Digital Content 1, http://links.lww.com/PCC/A472) were included in further analysis (n = 95,253). We defined the patient's first cardiac surgery as the primary surgery for the hospital admission. If the primary surgery was not identifiable by procedure day of service, age at time of surgery, or diagnosis code, the patient was excluded (n = 21,106). GCs classified by ICD-9 codes included the following; T21, T13/18, 22q11 deletion syndrome, Turner syndrome, Klinefelter syndrome, sex chromosome disorder not otherwise specified, Cri du chat, Prader-Willi, microdeletion syndrome, Marfan syndrome, General deletions, autosomal deletions, fragile X syndrome, neurofibromatosis, tuberous sclerosis, and multiple congenital anomalies (Appendix 1B, Supplemental Digital Content 1, http://links.lww.com/PCC/A472). GCs were grouped as T21, T13/18, 22q11 deletion syndrome, and the rest were combined as "other" GCs using group consensus with input from a geneticist (S.L.B.). These groups were compared with subjects with no known GC.
Subject level data including congenital heart defect, cardiac surgical procedure, coexisting medical conditions/complications (i.e., prematurity, low birth weight, intraventricular hemorrhage, bronchopulmonary dysplasia, primary and secondary pulmonary hypertension, acute renal failure, pulmonary hemorrhage, stroke, intracranial hemorrhage, and cardiac arrest), and additional procedures were based on ICD-9 codes. Cardiac anatomic diagnosis and surgery were validated by two investigators (J.M.F-D., S.L.B.) and discrepancies resolved by a third investigator (V.A.).
Primary Comparison
We compared subjects with GCs to those without to determine if their odds of death without ECMO, use of ECMO, or mortality with ECMO differed when adjusted for complexity of surgery and other confounders.
Secondary Comparisons
We reported cardiac surgery rates by known GCs over time.
Statistical Analysis
Data are reported as frequencies (n) and proportions (%) or as median values with interquartile range. To identify risk factors for ECMO and death, univariate analysis was performed using the chi-square or Wilcoxon rank-sum test. Variables associated with in-hospital death or ECMO were considered in a multivariable logistic regression models using forward stepwise regression with inclusion criteria of p value less than or equal to 0.1 and exclusion criteria of p value less than or equal to 0.05. The final models included factors that remained independently associated with mortality or ECMO. Complications that occur during ECMO were excluded from the model for odds of ECMO. Significance was defined as p value of less than or equal to 0.5 and when pairwise comparisons were made between study groups a Bonferroni adjustment was used. IBM SPSS (v. 25 for MAC; IBM, Armonk, NY) was used for analysis. 
RESULTS
After exclusion for patients who did not have a RACHS category score in the perioperative period, 95,253 cardiac surgery cases from 43 of the PHIS hospitals met the study criteria. Of these, 2,680 (2.8%) received ECMO during the same hospitalization. Cases with GCs comprised 15% (n = 14,713) of the study population; represented by T21 (n = 9,473, 10%), T13/18 (n = 156, 0.2%), 22q11 deletion syndrome (n = 715, 0.75%), and other GCs (n = 4,369, 5%). The subsets of the other GCs group included 2,305 (53%) with multiple congenital anomalies syndromes, 1,171 (27%) with single gene defects, 646 (15%) with sex chromosomes disorders, and 248 (6%) with copy number variants (excluding 22q11).
Patient Characteristics
Select cardiac case characteristics are compared by GCs in Table 1 . Age differed by study groups. The greatest difference was among patients with T21, 68% were 2-12 months (13) 20 (13) 90 (13) 884 (20) 5-10 yr 7,192 (9) 419 (4) 9 (6) 87 (8) 383 (9) > 10 yr 8,485 (11) 335 (4) 4 (3) 74 (11) 434 (10) Missing age 656 (1) (2) 3 (2) 27 (4) 96 (2) Other 9,252 (12) 1,076 (11) 13 (8) 75 (11) 444 (10) Missing race 2,750 (3) 302 (3) 12 (8) 21 (3) 147 (3) RACHS 1 categories, n (%) a RACHS 1 8,819 (11) 398 (4) 8 (5) 11 (2) (12) 187 (2) 11 (7) 188 (26) 477 (11) RACHS 5 133 (< 1)
Non-ECMO mortality, n (%) 1,252 (2) 128 (1) 15 (10) c 17 (2) 187 (4) In-hospital death, n (%) 2,344 (3) 194 ( old compared with 20-40% among the GCs groups and 29% among patients without a GC. The distribution of RACHS categories also varied by study groups (Table 1 and Fig. 1 ). Patients with T21 had the largest proportion of RACHS 3 surgeries (atrioventricular canal repair: n = 6,210, 66%), and those with T13/18 had greater proportion of RACHS 2 surgeries (ventricular septal defect repair: n = 15, 10%). Table 2 compares patients by receipt of ECMO and by inhospital survival. Neonates were the most likely to receive ECMO and die prior to hospital discharge. Comorbid conditions and medical complications were elevated in similar proportions in those receiving ECMO and in those who died.
Comparing Rates of ECMO Use and ECMO Mortality by GC
Compared with cardiac surgical cases without a GC, those with T21 received ECMO significantly less, whereas those with other GCs received ECMO more frequently (Table 1) . Patients with multiple congenital anomalies syndromes within the other GCs group were treated with ECMO significantly more than children without a GC (3.5%) (p = 0.0003), while the use of ECMO did not significantly differ for the remaining subsets.
Among children treated with ECMO in the other GCs group, the risk of death was significantly greater than in children without a GC on ECMO (relative risk [ 
Comparing Rates of Surgery Over Time
Over the 10-year study period, the proportion of patients undergoing cardiac surgery who had GCs did not vary over time compared with all patients who had cardiac surgery. The rates for all patients with and without a GC and specifically for children with T13/18 did not significantly increase.
Multivariable Logistic Regression Models for Odds of Receiving ECMO and ECMO Mortality
The results of the multivariable logistic regression models used to predict odds of mortality with and without ECMO as well as use of ECMO can be seen in Figure 2 . The model to predict odds of death with and without ECMO also controlled for additional medical complications: intraventricular hemorrhage, acute renal failure, pulmonary hemorrhage, stroke, and intracranial hemorrhage. These complications were not included in the regression model to predict odds of receiving ECMO, because the database does not specify the timing of medical complications so it is not possible to ascribe the event as result of ECMO or a complication leading to ECMO.
ECMO Use
Compared with patients without a known GC and adjusted for age, surgical complexity, comorbidities, and complications of care ( Fig. 2 and Table 3 ), the odds of receiving ECMO were significantly lower in T21 (odds ratio [OR], 0.54; 95% CI, 0.45-0.66). Cases with T13/18 and 22q11 had similar odds of receiving ECMO, whereas cases with other GCs had greater odds of ECMO receipt (OR, 1.22; 95% CI, 1.03-1.45).
Adjusted ECMO and Non-ECMO Mortality
Adjusted for age, surgical complexity, comorbidities, and complications of care, T21 had similar adjusted odds of mortality in those treated with ECMO while those with 22q11 deletion and other GCs had significantly increased adjusted odds of mortality compared with children without a GC who received ECMO. All five patients with T13/18 who received ECMO died prior to hospital discharge. Compared with children without a GC, the adjusted odds of death among patients not treated with ECMO were significantly greater for cases with T13/18 and cases of those with other GCs, but children with 22q11 and T21 had similar adjusted odds of death. The adjusted odds of death without ECMO are roughly two-fold greater than the adjusted odds of death with ECMO for those with other GCs.
DISCUSSION
In this large multicenter database study, we found that annual proportions of cardiac surgery for children with known GCs versus those without did not increase over the 10 years of study. Our hypothesis that ECMO would be withheld from those with GCs who may have benefitted from it was not demonstrated. For instance, children with T21 had significantly lower adjusted odds of receiving ECMO but similar adjusted odds of death with or without ECMO. Children with T13/18 and cardiac surgery die frequently and their ECMO mortality was 100% but the rate they received ECMO does not suggest that they were offered it significantly less. Children with 22q11 had similar odds of ECMO use but had increased odds of dying if they did receive ECMO. The mortality without ECMO in children with 22q11 was similar to those without GC. Finally, the other GCs group had increased odds of receiving ECMO compared with no GC and increased mortality with and without ECMO, though the odds of death without ECMO were almost twice than that of those with ECMO.
Previous studies regarding the prevalence of extracardiac abnormalities in CHD reported ranges of 17-30% (4, 5, 11, 12) . A recent analysis of the Society of Thoracic Surgeons Congenital Heart Surgery Database of GCs in neonates (< 30 d) with a cardiac operation from 2010 to 2013 reported a prevalence of 18.8% (13) . We identified a GC in 15% of cardiac surgical patients treated from 2003 to 2014. Our rate may differ because we included all pediatric ages and it also be affected by patients who had multiple procedures over the long study period. Patients with GCs would likely have lower rates of multiple palliative procedures but we did not have a unique patient number to link surgical cases to patients. Children with T13/18 had relatively noncomplex surgical repairs (92% RACHS 3 or lower) but still had the greatest rate of surgical mortality. Only five patients with T13/18 received a rescue trial of ECMO in the perioperative period and all five died. Some patients with T13/18 may not have received cardiac surgery, therefore, it is difficult to know we identified every patient to accurately predict mortality risk; however, we did find a similar amount of patients who received a cardiac procedure (n = 154) as a recent publication looking at the Kids' Inpatient Database from 1997 to 2009 (14) . These results indicate that although the surgical palliation rates are potentially shifting (15, 16) , both ECMO mortality and non-ECMO surgical mortality remain significantly elevated for these children.
Reluctance to treat T21 patients with ECMO in the past was likely due to a reported higher risk of post-ECMO morbidity and mortality reported in 2001 and 2007 (5, 8) . However, several recent studies confirm our finding of lower adjusted ECMO use but similar ECMO mortality for T21 patients treated in perioperative period compared with children without known GC (17, 18) . In 2015 using the Extracorporeal Life Support Organization (ELSO) registry, Cashen et al (19) found that children with T21 treated with ECMO for both cardiac and respiratory failure did not have increased risk of mortality compared with children without T21.
Use of ECMO was not increased for patients with 22q11 but the risk of death with ECMO was 3.5-fold higher compared with those without a GC; however, the precision of the estimate was poor with a wide CI. Studies directly assessing the association of 22q11 deletion syndrome and perioperative mortality are limited. O'Byrne et al (20) reported similar use of ECMO and hospital mortality of patients with 22q11 compared with other cardiac surgical patients, but significantly worse perioperative outcomes. A study using the ELSO registry of 88 patients with 22q11 deletion treated from 1998 to 2011 also did not find an increased risk of ECMO use or mortality despite ECMO (21) . This is in contrast to our findings, of the 33 patients with 22q11 who died after surgery in our study, 16 (52%) had received ECMO. Of those who did not receive ECMO, mortality was only 2%. Our analysis adjusted for surgical complexity and medical complications, but in close review, we find our patients had a similar surgical case mix in comparison with these previous studies. We cannot say with certainty why the findings of an increase in ECMO mortality are seen in our results but some potential explanations could be that these previous studies had a larger sample size of patients who received ECMO. Further studies would need to confirm this projected increased ECMO mortality risk.
In contrast to those with T21 and 22q11 deletion syndrome, children with other GCs had significantly greater adjusted odds of receiving ECMO, and both greater odds of death with and without ECMO compared with children without a GC. Similar to our findings, Alsoufi et al (11) reported that despite adjustment for prematurity and low birth weight, children with GCs had significantly increased risk of death after cardiac surgery compared with children without a GC. Furthermore, after surgery, at 10-year follow-up, survival remained lower among children with GCs compared with those with no GCs. Multiple studies describe increased mortality at stage I palliation for infants with GC (22) (23) (24) . It is not surprising that patients with multiple organ system dysfunction would have greater ECMO mortality. Patients with 22q11 syndrome have known impaired immunologic function and impaired T cell production, which Figure 2 . Multivariable logistic regression models for odds of extracorporeal membrane oxygenation (ECMO) (A) and odds of mortality with (B) and without ECMO (C). All models controlled for age, Risk Adjustment for Congenital Heart Surgery (RACHS) score, genetic condition (GC), prematurity, and comorbid conditions. The reference groups in the models were as follows: age 0-30 d, RACHS 1-2, no GC, and no comorbidity. OR = odds ratio. increases the risk of infection. The rates of infection on ECMO are reported as high as 11.7% even without the additional factor of an impaired immune system (25) . The increased ECMO mortality we identified in those with 22q11 could be secondary to this increased infection risk. In our cohort, those with 22q11 had an occurrence of a nosocomial infection of 3.3%, which was three times higher than the rate of nosocomial infection in those with no GCs.
We acknowledge that the other GCs group is heterogeneous but evaluation by subgroups still showed an increase in unadjusted risk of receiving ECMO and increased risk of death if ECMO was not used among all subgroups. The subgroup that comprises the greatest percentage of the other category is multiple congenital anomalies. The ICD-9 code for multiple congenital anomalies is used for GCs that comprise complications of multiple organ systems (i.e., CHARGE syndrome, VACTERL association, etc.). It is likely inaccurate to conclude that every GC in our other group has equal elevated risk of ECMO use and slightly increased ECMO mortality. Despite the fact that the mortality among surgical cases not supported with ECMO is substantially elevated (4.4%), if the child does not have other complications making successful rescue with ECMO likely, the current 50% ECMO mortality should not dissuade increased use for patients with these GCs until more sufficient granular information regarding ECMO mortality is available. ). All models controlled for age, RACHS score, genetic conditions (GC), prematurity, and comorbid conditions. The reference groups in the models were as follows: age 0-30 d, RACHS 1-2, no GC, and no comorbidity.
Although the data in this study do not provide sufficient information to judge proper ECMO candidacy among cardiac surgery patients, the information provided can be used to help clinicians evaluate risk versus benefit. Because ECMO is usually employed as a rescue therapy, the decision to use it is time sensitive; therefore, a better understanding of additional risk factors for mortality is important.
This study is subject to limitations applicable to all retrospective observational studies including human error for data entry despite quality control measures and use of multiple ICD-9 diagnostic and surgical codes for a single patient. We excluded surgical cases that did not have clear cardiac anatomic diagnosis and surgery to reduce diagnostic bias, but we were unable to account for the fact that some patients had multiple procedures over the long study period. While we can conclude that the proportion of patients with GCs and cardiac surgery compared with all patients who had cardiac surgery per year did not significantly increase over time, this conclusion does not account for patients whose families chose nonsurgical options or patients who were not offered surgery. Therefore, the proportion of children with GCs receiving cardiac surgery remains unknown. Another limitation is the ability to categorize the timing of the comorbidities on ECMO. It is unknown whether these events occurred prior to initiation of ECMO or as a consequence of ECMO because ICD-9 Clinical Modification codes are collected primarily for billing purposes and are not assigned to a specific hospital day. In our description of patient characteristics and outcomes, we were limited by the variables collected in PHIS database, which do not include physiologic information to calculate to severity of illness scores or progression of organ dysfunction during hospitalization.
CONCLUSIONS
The presence of most GCs, excluding T21, have increased mortality with cardiac surgery. Children with T13/18 had the highest mortality rate, and in our study, the small number of patients who received ECMO had 100% mortality. ECMO was employed as a rescue therapy among all GCs groups during their surgical care, but ECMO mortality was significantly greater for those with 22q11 deletion and other GCs. Children with other GCs have increased odds of ECMO use and dying with or without ECMO utilization. GC should be considered a potential risk factor for greater hospital mortality with cardiac surgery and when considering ECMO to rescue patients in the perioperative period. Future evaluation should include delineations of other GCs in more detail to better identify their cardiac surgery and ECMO mortality risks.
